Iovance Biotherapeutics (NASDAQ: IOVA) has reached a major turning point in its story as a company. Later this month, the U.S. Food and Drug Administration (FDA) is set to issue a decision on what could become the company's first commercialized product developed in house. Regulators are reviewing lifileucel for advanced melanoma, the most dangerous form of skin cancer.

In spite of this upcoming -- and potentially positive -- catalyst, Iovance stock has been in the doldrums for quite some time. In fact, the shares have lost more than 80% over the past three years. Now, though, with a possible new revenue source on the horizon, is Iovance a buy? Let's find out.

Image source: Getty Images.

Continue reading

Source Fool.com